Oxidative stress in Alzheimer's disease: Are we connecting the dots?

Journal of Medicinal Chemistry

Volumn 57, Issue 7, 2014, Pages 2821-2831

  Rosini, Michela ^a   Simoni, Elena ^a   Milelli, Andrea ^a   Minarini, Anna ^a   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; CURCUMIN; ELECTROPHILE; FREE RADICAL; POLYPHENOL; SYNAPSIN I;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; BIOLOGICAL ACTIVITY; CELL DAMAGE; CELL DEATH; CELL ENERGY; CELL FUNCTION; COGNITION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SAFETY; ENANTIOMER; FREE RADICAL SCAVENGING ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; IN VIVO STUDY; INTRACELLULAR SPACE; LIPID PEROXIDATION; LIPID RAFT; MEMORY; NERVE CELL MEMBRANE; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SUBMITOCHONDRIAL PARTICLE;

ALZHEIMER DISEASE; ANTIOXIDANTS; HUMANS; OXIDATIVE STRESS;

EID: 84898425209     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400970m     Document Type: Review

References (87)

1. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease Lancet 2011, 377, 1019-1031
2. Wolfe, M. S. Introduction to special issue on Alzheimer's disease J. Med. Chem. 2012, 55, 8977-8978
3. von Bernhardi, R.; Eugenin, J. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms Antioxid. Redox Signaling 2012, 16, 974-1031
4. Feng, Y.; Wang, X. Antioxidant therapies for Alzheimer's disease Oxid. Med. Cell. Longevity 2012, 2012, 472932
5. Pratico, D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal Trends Pharmacol. Sci. 2008, 29, 609-615
6. Sultana, R.; Mecocci, P.; Mangialasche, F.; Cecchetti, R.; Baglioni, M.; Butterfield, D. A. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder J. Alzheimer's Dis. 2011, 24, 77-84
7. Moreira, P. I.; Nunomura, A.; Nakamura, M.; Takeda, A.; Shenk, J. C.; Aliev, G.; Smith, M. A.; Perry, G. Nucleic acid oxidation in Alzheimer disease Free Radical Biol. Med. 2008, 44, 1493-1505
8. Fukuda, M.; Kanou, F.; Shimada, N.; Sawabe, M.; Saito, Y.; Murayama, S.; Hashimoto, M.; Maruyama, N.; Ishigami, A. Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease Biomed. Res. 2009, 30, 227-233
9. Sultana, R.; Butterfield, D. A. Role of oxidative stress in the progression of Alzheimer's disease J. Alzheimer's Dis. 2010, 19, 341-353
10. Markesbery, W. R. Oxidative stress hypothesis in Alzheimer's disease Free Radical Biol. Med. 1997, 23, 134-147
11. Mecocci, P.; Polidori, M. C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease Biochim. Biophys. Acta 2012, 1822, 631-638
12. Becker, R. E.; Greig, N. H.; Giacobini, E. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J. Alzheimer's Dis. 2008, 15, 303-325
13. Fazil, M.; Shadab; Baboota, S.; Sahni, J. K.; Ali, J. Nanotherapeutics for Alzheimer's disease (AD): past, present and future J. Drug Targeting 2012, 20, 97-113
14. Galasko, D. R.; Peskind, E.; Clark, C. M.; Quinn, J. F.; Ringman, J. M.; Jicha, G. A.; Cotman, C.; Cottrell, B.; Montine, T. J.; Thomas, R. G.; Aisen, P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures Arch. Neurol. 2012, 69, 836-841
15. Trippier, P. C.; Jansen Labby, K.; Hawker, D. D.; Mataka, J. J.; Silverman, R. B. Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers J. Med. Chem. 2013, 56, 3121-3147
16. Zhang, H. Y.; Yang, D. P.; Tang, G. Y. Multipotent antioxidants: from screening to design Drug Discovery Today 2006, 11, 749-754
17. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
18. Bolognesi, M. L.; Matera, R.; Minarini, A.; Rosini, M.; Melchiorre, C. Alzheimer's disease: new approaches to drug discovery Curr. Opin. Chem. Biol. 2009, 13, 303-308
19. Tailor, N.; Sharma, M. Antioxidant hybrid compounds: a promising therapeutic intervention in oxidative stress induced diseases Mini-Rev. Med. Chem. 2013, 13, 280-297
20. Weinreb, O.; Amit, T.; Bar-Am, O.; Yogev-Falach, M.; Youdim, M. B the neuroprotective mechanism of action of the multimodal drug ladostigil Front. Biosci. 2008, 13, 5131-5137
21. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M. B. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment Curr. Drug Targets 2012, 13, 483-494
22. Silman, I.; Sussman, J. L. Acetylcholinesterase: "classical" and "non-classical" functions and pharmacology Curr. Opin. Pharmacol. 2005, 5, 293-302
23. Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Melchiorre, C. From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease Mini-Rev. Med. Chem. 2008, 8, 960-967
24. Munoz-Torrero, D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease Curr. Med. Chem. 2008, 15, 2433-2455
25. Inestrosa, N. C.; Dinamarca, M. C.; Alvarez, A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease FEBS J. 2008, 275, 625-632
26. Castro, A.; Martinez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors Curr. Pharm. Des. 2006, 12, 4377-4387
27. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs J. Med. Chem. 2005, 48, 360-363
28. Rosini, M.; Simoni, E.; Bartolini, M.; Tarozzi, A.; Matera, R.; Milelli, A.; Hrelia, P.; Andrisano, V.; Bolognesi, M. L.; Melchiorre, C. Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease Eur. J. Med. Chem. 2011, 46, 5435-5442
29. Tirosh, O.; Sen, C. K.; Roy, S.; Kobayashi, M. S.; Packer, L. Neuroprotective effects of alpha-lipoic acid and its positively charged amide analogue Free Radical Biol. Med. 1999, 26, 1418-1426
30. Bertucci, C.; De Simone, A.; Pistolozzi, M.; Rosini, M. Reversible human serum albumin binding of lipocrine: a circular dichroism study Chirality 2011, 23, 827-832
31. Rosini, M.; Andrisano, V.; Bartolini, M.; Melchiorre, C. Tetrahydro-acridine and Dithiolane Derivatives. US7307083B2, 2007.
32. Minarini, A.; Milelli, A.; Simoni, E.; Rosini, M.; Bolognesi, M. L.; Marchetti, C.; Tumiatti, V. Multifunctional tacrine derivatives in Alzheimer's disease Curr. Top. Med. Chem. 2013, 13, 1771-1786
33. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease Angew. Chem., Int. Ed. 2007, 46, 3689-3692
34. Bolognesi, M. L.; Cavalli, A.; Bergamini, C.; Fato, R.; Lenaz, G.; Rosini, M.; Bartolini, M.; Andrisano, V.; Melchiorre, C. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks J. Med. Chem. 2009, 52, 7883-7886
35. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D. W.; Tarozzi, A.; Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I. R.; Melchiorre, C. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush J. Med. Chem. 2008, 51, 4381-4384
36. Minarini, A.; Milelli, A.; Tumiatti, V.; Rosini, M.; Simoni, E.; Bolognesi, M. L.; Andrisano, V.; Bartolini, M.; Motori, E.; Angeloni, C.; Hrelia, S. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment Neuropharmacology 2012, 62, 997-1003
37. Pi, R.; Mao, X.; Chao, X.; Cheng, Z.; Liu, M.; Duan, X.; Ye, M.; Chen, X.; Mei, Z.; Liu, P.; Li, W.; Han, Y. Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-beta-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo PLoS One 2012, 7, e31921
38. 50) of compound 5: Pi, R. S. Y.-S. U., Guangzhow, China. Personal communication, 2013.
39. Coma, M.; Guix, F. X.; Ill-Raga, G.; Uribesalgo, I.; Alameda, F.; Valverde, M. A.; Munoz, F. J. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells Neurobiol. Aging 2008, 29, 969-980
40. Butterfield, D. A.; Swomley, A. M.; Sultana, R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression Antioxid. Redox Signaling 2013, 19, 823-835
41. Takeda, S.; Sato, N.; Niisato, K.; Takeuchi, D.; Kurinami, H.; Shinohara, M.; Rakugi, H.; Kano, M.; Morishita, R. Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease Brain Res. 2009, 1280, 137-147
42. Sun, A. Y.; Wang, Q.; Simonyi, A.; Sun, G. Y. Botanical phenolics and brain health NeuroMol. Med. 2008, 10, 259-274
43. Motterlini, R.; Foresti, R.; Bassi, R.; Green, C. J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress Free Radical Biol. Med. 2000, 28, 1303-1312
44. Belkacemi, A.; Doggui, S.; Dao, L.; Ramassamy, C. Challenges associated with curcumin therapy in Alzheimer disease Expert Rev. Mol. Med. 2011, 13, e34
45. Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B. B. Bioavailability of curcumin: problems and promises Mol. Pharmaceutics 2007, 4, 807-818
46. Dolai, S.; Shi, W.; Corbo, C.; Sun, C.; Averick, S.; Obeysekera, D.; Farid, M.; Alonso, A.; Banerjee, P.; Raja, K. "Clicked" sugar-curcumin conjugate: modulator of amyloid-beta and tau peptide aggregation at ultralow concentrations ACS Chem. Neurosci. 2011, 2, 694-699
47. Evangelisti, E.; Wright, D.; Zampagni, M.; Cascella, R.; Fiorillo, C.; Bagnoli, S.; Relini, A.; Nichino, D.; Scartabelli, T.; Nacmias, B.; Sorbi, S.; Cecchi, C. Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer's disease Curr. Alzheimer Res. 2013, 10, 143-153
48. Ariga, T.; McDonald, M. P.; Yu, R. K. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease - a review J. Lipid Res. 2008, 49, 1157-1175
49. Lenhart, J. A.; Ling, X.; Gandhi, R.; Guo, T. L.; Gerk, P. M.; Brunzell, D. H.; Zhang, S. "Clicked" bivalent ligands containing curcumin and cholesterol as multifunctional abeta oligomerization inhibitors: design, synthesis, and biological characterization J. Med. Chem. 2010, 53, 6198-6209
50. Liu, K.; Guo, T. L.; Chojnacki, J.; Lee, H. G.; Wang, X.; Siedlak, S. L.; Rao, W.; Zhu, X.; Zhang, S. Bivalent ligand containing curcumin and cholesterol as fluorescence probe for Abeta plaques in Alzheimer's disease ACS Chem. Neurosci. 2012, 3, 141-146
51. Liu, K.; Gandhi, R.; Chen, J.; Zhang, S. Bivalent ligands targeting multiple pathological factors involved in Alzheimer's disease ACS Med. Chem. Lett. 2012, 3, 942-946
52. Baum, L.; Ng, A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models J. Alzheimer's Dis. 2004, 6, 367-377
53. Innocenti, M.; Salvietti, E.; Guidotti, M.; Casini, A.; Bellandi, S.; Foresti, M. L.; Gabbiani, C.; Pozzi, A.; Zatta, P.; Messori, L. Trace copper(II) or zinc(II) ions drastically modify the aggregation behavior of amyloid-beta1-42: an AFM study J. Alzheimer's Dis. 2010, 19, 1323-1329
54. Rajendran, R.; Minqin, R.; Ynsa, M. D.; Casadesus, G.; Smith, M. A.; Perry, G.; Halliwell, B.; Watt, F. A novel approach to the identification and quantitative elemental analysis of amyloid deposits - insights into the pathology of Alzheimer's disease Biochem. Biophys. Res. Commun. 2009, 382, 91-95
55. Eskici, G.; Axelsen, P. H. Copper and oxidative stress in the pathogenesis of Alzheimer's disease Biochemistry 2012, 51, 6289-6311
56. Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. Untangling amyloid-beta, tau, and metals in Alzheimer's disease ACS Chem. Biol. 2013, 8, 856-865
57. Sopher, B. L.; Fukuchi, K.; Kavanagh, T. J.; Furlong, C. E.; Martin, G. M. Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death Mol. Chem. Neuropathol. 1996, 29, 153-168
58. Lin, M. T.; Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 2006, 443, 787-795
59. Ankarcrona, M.; Mangialasche, F.; Winblad, B. Rethinking Alzheimer's disease therapy: Are mitochondria the key? J. Alzheimer's Dis. 2010, 20 (Suppl. 2) S579-S590
60. Chaturvedi, R. K.; Beal, M. F. Mitochondrial approaches for neuroprotection Ann. N.Y. Acad. Sci. 2008, 1147, 395-412
61. Reddy, P. H.; Tripathi, R.; Troung, Q.; Tirumala, K.; Reddy, T. P.; Anekonda, V.; Shirendeb, U. P.; Calkins, M. J.; Reddy, A. P.; Mao, P.; Manczak, M. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics Biochim. Biophys. Acta 2012, 1822, 639-649
62. Leuner, K.; Muller, W. E.; Reichert, A. S. From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease Mol. Neurobiol. 2012, 46, 186-193
63. Reddy, P. H.; Beal, M. F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease Trends Mol. Med. 2008, 14, 45-53
64. Edeas, M. Strategies to target mitochondria and oxidative stress by antioxidants: key points and perspectives Pharm. Res. 2011, 28, 2771-2779
65. Murphy, M. P.; Smith, R. A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations Annu. Rev. Pharmacol. Toxicol. 2007, 47, 629-656
66. Gruber, J.; Fong, S.; Chen, C. B.; Yoong, S.; Pastorin, G.; Schaffer, S.; Cheah, I.; Halliwell, B. Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing Biotechnol. Adv. 2013, 31, 563-592
67. Carroll, R. E.; Benya, R. V.; Turgeon, D. K.; Vareed, S.; Neuman, M.; Rodriguez, L.; Kakarala, M.; Carpenter, P. M.; McLaren, C.; Meyskens, F. L., Jr.; Brenner, D. E. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia Cancer Prev. Res. 2011, 4, 354-364
68. Simoni, E.; Bergamini, C.; Fato, R.; Tarozzi, A.; Bains, S.; Motterlini, R.; Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Hrelia, P.; Lenaz, G.; Rosini, M.; Melchiorre, C. Polyamine conjugation of curcumin analogues toward the discovery of mitochondria-directed neuroprotective agents J. Med. Chem. 2010, 53, 7264-7268
69. Youssef, K. M.; El-Sherbeny, M. A.; El-Shafie, F. S.; Farag, H. A.; Al-Deeb, O. A.; Awadalla, S. A. Synthesis of curcumin analogues as potential antioxidant, cancer chemopreventive agents Arch. Pharm. (Weinheim, Ger.) 2004, 337, 42-54
70. Dimmock, J. R.; Arora, V. K.; Chen, M.; Allen, T. M.; Kao, G. Y. Cytotoxic evaluation of some N -acyl and N -acyloxy analogues of 3,5-bis(arylidene)-4-piperidones Drug Des. Discovery 1994, 12, 19-28
71. Brel, V.; Annereau, J. P.; Vispe, S.; Kruczynski, A.; Bailly, C.; Guilbaud, N. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II Biochem. Pharmacol. 2011, 82, 1843-1852
72. Poduslo, J. F.; Curran, G. L. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers J. Neurochem. 1996, 66, 1599-1609
73. Rajendran, L.; Knolker, H. J.; Simons, K. Subcellular targeting strategies for drug design and delivery Nat. Rev. Drug Discovery 2010, 9, 29-42
74. Halliwell, B the wanderings of a free radical Free Radical Biol. Med. 2009, 46, 531-542
75. Wilson, A. J.; Kerns, J. K.; Callahan, J. F.; Moody, C. J. Keap calm, and carry on covalently J. Med. Chem. 2013, 56, 7463-7476
76. Dumont, M.; Beal, M. F. Neuroprotective strategies involving ROS in Alzheimer disease Free Radical Biol. Med. 2011, 51, 1014-1026
77. Suzuki, T.; Motohashi, H.; Yamamoto, M. Toward clinical application of the Keap1-Nrf2 pathway Trends Pharmacol. Sci. 2013, 34, 340-346
78. Satoh, T.; Lipton, S. A. Redox regulation of neuronal survival mediated by electrophilic compounds Trends Neurosci. 2007, 30, 37-45
79. Magesh, S.; Chen, Y.; Hu, L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents Med. Res. Rev. 2012, 32, 687-726
80. Lee, D. H.; Stangel, M.; Gold, R.; Linker, R. A the fumaric acid ester BG-12: a new option in MS therapy Expert Rev. Neurother. 2013, 13, 951-958
81. Linker, R. A.; Lee, D. H.; Ryan, S.; van Dam, A. M.; Conrad, R.; Bista, P.; Zeng, W.; Hronowsky, X.; Buko, A.; Chollate, S.; Ellrichmann, G.; Bruck, W.; Dawson, K.; Goelz, S.; Wiese, S.; Scannevin, R. H.; Lukashev, M.; Gold, R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway Brain 2011, 134, 678-692
82. Pace, N. J.; Weerapana, E. Diverse functional roles of reactive cysteines ACS Chem. Biol. 2013, 8, 283-296
83. Lipton, S. A. Pathologically activated therapeutics for neuroprotection Nat. Rev. Neurosci. 2007, 8, 803-808
84. Satoh, T.; Saitoh, S.; Hosaka, M.; Kosaka, K. Simple ortho- and para-hydroquinones as compounds neuroprotective against oxidative stress in a manner associated with specific transcriptional activation Biochem. Biophys. Res. Commun. 2009, 379, 537-541
85. Lo, S. C.; Li, X.; Henzl, M. T.; Beamer, L. J.; Hannink, M. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling EMBO J. 2006, 25, 3605-3617
86. Hu, L.; Magesh, S.; Chen, L.; Wang, L.; Lewis, T. A.; Chen, Y.; Khodier, C.; Inoyama, D.; Beamer, L. J.; Emge, T. J.; Shen, J.; Kerrigan, J. E.; Kong, A. N.; Dandapani, S.; Palmer, M.; Schreiber, S. L.; Munoz, B. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction Bioorg. Med. Chem. Lett. 2013, 23, 3039-3043
87. Marcotte, D.; Zeng, W.; Hus, J. C.; McKenzie, A.; Hession, C.; Jin, P.; Bergeron, C.; Lugovskoy, A.; Enyedy, I.; Cuervo, H.; Wang, D.; Atmanene, C.; Roecklin, D.; Vecchi, M.; Vivat, V.; Kraemer, J.; Winkler, D.; Hong, V.; Chao, J.; Lukashev, M.; Silvian, L. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism Bioorg. Med. Chem. 2013, 21, 4011-4019